✦ LIBER ✦

PCN20 COSTS OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER IN SPAIN USING GEMCITABINE IN COMBINATION WITH CISPLATIN: A COMPARISON WITH OTHER 2ND GENERATION NOVEL AGENTS

✍ Scribed by A Kielhorn; T Dilla; G Stynes; D Tilden; S Bhalla

Book ID: 119596613
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 64 KB
Volume: 7
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)65754-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

93P A COMPARATIVE STUDY OF DOCETAXEL PLU

93P A COMPARATIVE STUDY OF DOCETAXEL PLUS CISPLATIN COMPARED WITH GEMCITABINE PLUS CISPLATIN IN TREATING ADVANCED NON-SMALL CELL LUNG CANCER

✍ ElHindawy, E. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 44 KB

PCNI8 A COST COMPARISON OF GEMZAR PLUS C

PCNI8 A COST COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY

✍ A Kielhorn; G Stynes; S Bhalla; D Tilden 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Gefitinib in Combination With Gemcitabin

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial--INTACT 1

✍ Giaccone, G. 📂 Article 📅 2004 🏛 American Society of Clinical Oncology 🌐 English ⚖ 430 KB

159 Phase II trial of gemcitabine in com

159 Phase II trial of gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer (NSCLC)

✍ Mohedano, N.; Sanchez-Rovira, P.; Medina, B.; Flores-Gonzalez, E.; Moreno, M.A.; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

## Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, placebo-controlled, multicenter trial evaluated th